Velpatasvir

Velpatasvir

Clinical data
Trade names	Epclusa, Sofosvel (in combination with sofosbuvir)
Routes of administration	Oral (tablets)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	>99.5%
Metabolism	Liver (CYP2B6, 2C8, 3A4)
Elimination half-life	15 hours
Excretion	Feces (94%), urine (0.4%)
Identifiers
IUPAC name Methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)-2-pyrrolidinyl]-1H-imidazol-4-yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methyl-1-pyrrolidinyl]-3-methyl-1-oxo-2-butanyl}carbamate
CAS Number	1377049-84-7
PubChem CID	67683363
DrugBank	DB11613
ChemSpider	34501056
UNII	KCU0C7RS7Z
ChEBI	CHEBI:133009 Y
CompTox Dashboard (EPA)	DTXSID70722565
Chemical and physical data
Formula	C49H54N8O8
Molar mass	883.019 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H]1CC[C@H](N1C(=O)[C@H](C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)[C@@H]8C[C@@H](CN8C(=O)[C@@H](C9=CC=CC=C9)NC(=O)OC)COC
InChI InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1 Key:FHCUMDQMBHQXKK-CDIODLITSA-N

Velpatasvir is an NS5A inhibitor which is used together with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes.

See also

• Velpatasvir/sofosbuvir, with more information about the drug combination
• Discovery and development of NS5A inhibitors